Literature DB >> 31289143

Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease.

Myung Jun Lee1, Kyoungjune Pak2, Jong Hun Kim2, Yun Joong Kim2, Jeehee Yoon2, Jinwoo Lee1, Chul Hyoung Lyoo2, Hyung Jun Park2, Jae-Hyeok Lee1, Na-Yeon Jung2.   

Abstract

OBJECTIVE: To investigate the effect of polygenic load on the progression of striatal dopaminergic dysfunction in patients with Parkinson disease (PD).
METHODS: Using data from 335 patients with PD in the Parkinson's Progression Markers Initiative (PPMI) database, we investigated the longitudinal association of PD-associated polygenic load with changes in striatal dopaminergic activity as measured by 123I-N-3-fluoropropyl-2-β-carboxymethoxy-3β-(4-iodophenyl) nortropane (123I-FP-CIT) SPECT over 4 years. PD-associated polygenic load was estimated by calculating weighted genetic risk scores (GRS) using 1) all available 27 PD-risk single nucleotide polymorphisms (SNPs) in the PPMI database (GRS1) and 2) 23 SNPs with minor allele frequency >0.05 (GRS2).
RESULTS: GRS1 and GRS2 were correlated with younger age at onset in patients with PD (GRS1, Spearman ρ = -0.128, p = 0.019; GRS2, Spearman ρ = -0.109, p = 0.047). Although GRS1 did not show an association with changes in striatal 123I-FP-CIT availability, GRS2 was associated with a slower decline of striatal dopaminergic activity (interactions with disease duration in linear mixed model; caudate nucleus, estimate = 0.399, SE = 0.165, p = 0.028; putamen, estimate = 0.396, SE = 0.137, p = 0.016).
CONCLUSIONS: Our results suggest that genetic factors for PD risk may have heterogeneous effects on striatal dopaminergic degeneration, and some factors may be associated with a slower decline of dopaminergic activity. Composition of PD progression-specific GRS may be useful in predicting disease progression in patients.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31289143     DOI: 10.1212/WNL.0000000000007939

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Genome Sequencing in the Parkinson Disease Clinic.

Authors:  Emily J Hill; Laurie A Robak; Rami Al-Ouran; Jennifer Deger; Jamie C Fong; Paul Jerrod Vandeventer; Emily Schulman; Sindhu Rao; Hiba Saade; Joseph M Savitt; Rainer von Coelln; Neeja Desai; Harshavardhan Doddapaneni; Sejal Salvi; Shannon Dugan-Perez; Donna M Muzny; Amy L McGuire; Zhandong Liu; Richard A Gibbs; Chad Shaw; Joseph Jankovic; Lisa M Shulman; Joshua M Shulman
Journal:  Neurol Genet       Date:  2022-06-09

2.  Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease.

Authors:  Myung Jun Lee; Kyoungjune Pak; Han-Kyeol Kim; Kelly N Nudelman; Jong Hun Kim; Yun Hak Kim; Junho Kang; Min Seok Baek; Chul Hyoung Lyoo
Journal:  NPJ Parkinsons Dis       Date:  2021-11-26

3.  Effects of Alzheimer's genetic risk scores and CSF biomarkers in de novo Parkinson's Disease.

Authors:  Young-Gun Lee; Seong Ho Jeong; Mincheol Park; Sung Woo Kang; Kyoungwon Baik; Seun Jeon; Phil Hyu Lee; Young Ho Sohn; Byoung Seok Ye
Journal:  NPJ Parkinsons Dis       Date:  2022-05-11

Review 4.  Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management.

Authors:  Xylena Reed; Artur Schumacher-Schuh; Jing Hu; Sara Bandres-Ciga
Journal:  J Pers Med       Date:  2021-03-01

5.  Interaction of CSF α-synuclein and amyloid beta in cognition and cortical atrophy.

Authors:  Young-Gun Lee; Seun Jeon; Sung Woo Kang; Mincheol Park; Kyoungwon Baik; Han Soo Yoo; Seok Jong Chung; Seong Ho Jeong; Jin Ho Jung; Phil Hyu Lee; Young Ho Sohn; Alan C Evans; Byoung Seok Ye
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.